Integumen PLC Board Appointment & Admission of Shares (8721X)
May 02 2019 - 2:18AM
UK Regulatory
TIDMSKIN
RNS Number : 8721X
Integumen PLC
02 May 2019
2 May 2019
Integumen PLC
("Integumen" or "Company")
Appointment of RinoCloud MD, Fionán Murray, to the Board
Admission of New Ordinary Shares
Further to the Company's announcements on 12 April 2019 and 30
April 2019, the Company confirms that Admission of the New Ordinary
Shares (as defined in the 12 April 2019 announcement) took place at
8.00 a.m. this morning. Following Admission Mr Fionán Murray is
confirmed as having joined the Board of Integumen as a
director.
Gerard Brandon, Chief Executive Officer, commented:
"We thank our existing and new investors for their investment.
Their continued support demonstrates confidence in our strategy and
vision to grow Integumen into a leader in virtual microbiology
testing company. Over the last five years, Labskin has established
itself as an approved supplier of products and services into a
large portfolio of blue-chip skincare, pharma, personal care, wound
care and health care clients across the US, EU and Asia. Fionán
Murray brings extensive expertise in the sales, innovation,
collation and maintenance of secure cloud-based sensitive
scientific data and his appointment underpins our commitment to
deliver sustained growth and drive value for our shareholders."
Board appointment
Fionán Murray has joined Integumen as Group Sales Director, and
as a Director of the Company with a focus on extending digital
services on top of existing Labskin physical services to rapidly
grow the Labskin AI footprint.
As Managing Director of RinoCloud Fionán Murray oversaw the
development of a range of software services dedicated to data
management - its security, storage, curation and analysis - which
generated interest from large blue-chip clients in Government,
Financial Services, Healthcare and Scientific Research. Beta
software deployments throughout 2017 have provided:
-- GDPR data management compliance for government;
-- Secure data collaboration between large financial services
groups and their customers/distribution channels;
-- Secure data curation and collaboration for research and development groups; and
-- Big science data analysis using AI.
These existing sales, marketing and distribution channels
provide the opportunity for cross selling complementary digital and
physical testing services currently being rolled out as part of the
Labskin AI eco-system. This incorporates the data management and
analytic services already built into Labskin AI by the RinoCloud
integration.
Total Voting Rights
The issued share capital of the Company now comprises
953,173,684 Ordinary Shares with one voting right per share. The
above figure may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Further information in relation to Fionán Murray
Save for the information above and below, there are no further
disclosures to be made in accordance with Rule 17, Schedule 2(g) of
the AIM Rules for Companies in respect of the appointment Fionán
Murray.
Full name: Fionán Murray
Age: 54 years old
Mr Murray currently holds the following directorships:
RinoCloud Limited
Small Business Base Limited (trading name: Hydrolight)
The Drive4Growth Company Limited
Monea Marketing Ltd
In the last five years, Mr Murray held the following
directorships:
N/A
Mr Murray holds 86,783,068 new Ordinary Shares which represents
9.10 per cent. of the issued share capital of the Company.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have
been deemed inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 until the release of this
announcement.
Enquiries:
+44 (0) 7340 055
Integumen plc Gerard Brandon, CEO 643
SPARK Advisory Partners
Limited Neil Baldwin/Vassil
(Nominated Adviser) Kirtchev +44 (0) 113 370 8974
Turner Pope Investments
(TPI) Limited
(Broker) Andy Thacker +44 (0) 20 3621 4120
About Integumen
Integumen is a vertically integrated business, collaborating
their Labskin technology platform with partners in artificial
intelligence, clinical research, medical device and life science.
These collaborators are building their own technology on top of the
Labskin AI backbone. Labskin allows skin-care, health-care,
pharmaceutical manufacturers and cosmetic companies to test their
products on human-like skin in a real-world environment with full
access to multiple state-of-the-art partner technologies.
The Company combines data analytics with access to therapeutic
operational expertise and offers solutions to our clients, from
regulatory approvals, right through to marketing fully tested
ingredients that have been certified on our Laboratory grown living
human tissue.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCCKBDDOBKKPPK
(END) Dow Jones Newswires
May 02, 2019 03:18 ET (07:18 GMT)
Integumen (LSE:SKIN)
Historical Stock Chart
From Apr 2024 to May 2024
Integumen (LSE:SKIN)
Historical Stock Chart
From May 2023 to May 2024